评价血管内皮生长因子（VEGF）和血小板反应蛋白-1 作为进展性儿科实体恶性肿瘤节拍化疗的生物标志物。

Evaluation of Vascular Endothelial Growth Factor (VEGF) and Thrombospondin-1 as Biomarkers of Metronomic Chemotherapy in Progressive Pediatric Solid Malignancies.

机构信息

Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India.

Department of Paediatric Surgrery, All India Institute of Medical Sciences, New Delhi, India.

出版信息

Indian Pediatr. 2020 Jun 15;57(6):508-511. Epub 2020 Mar 12.

PMID:32221052

Abstract

OBJECTIVE

We compared Vascular Endothelial Growth factor (VEGF) and Thrombospondin-1 between patients with progressive paediatric malignancies randomized to metronomic chemotherapy versus placebo to determine their role as biomarker.

METHODS

In this double-blinded, placebo-controlled randomized study of 108 progressive pediatric malignancies, serum VEGF and thrombospondin-1 levels were evaluated using ELISA at baseline, A2 (week-9 or earlier if progressed) and A3 (week-18 or earlier if progressed).

RESULTS

Mean VEGF and thrombospondin-1 at baseline, A2 and A3 and the change from baseline to A2 were not different between two groups. In metronomic arm, responders (those completing 3 cycles) had significantly lower mean (SD) baseline VEGF levels [659.7(362.1) vs 1143.9 (622.0) µg/mL] (P=0.002) and significant decrease in thrombospondin-1 from baseline to A2 [-4.43(8.0) µg/mL vs 1.7(11.3) µg/mL] (P=0.04), as compared to non-responders. Similar changes were not observed in responders on placebo arm. No consistent trend of these biomarkers was observed.

CONCLUSIONS

VEGF and thrombospondin-1 are not reliable biomarkers for response to metronomic chemotherapy.

摘要

目的

我们比较了接受节拍化疗与安慰剂治疗的进展性儿科恶性肿瘤患者的血管内皮生长因子（VEGF）和血栓素-1，以确定它们作为生物标志物的作用。

方法

在这项针对 108 例进展性儿科恶性肿瘤的双盲、安慰剂对照随机研究中，使用 ELISA 在基线、A2（如果进展则在第 9 周或更早）和 A3（如果进展则在第 18 周或更早）时评估血清 VEGF 和血栓素-1 水平。

结果

两组之间基线、A2 和 A3 的 VEGF 和血栓素-1 平均值以及从基线到 A2 的变化均无差异。在节拍化疗组中，应答者（完成 3 个周期的患者）的基线 VEGF 水平明显较低[659.7（362.1）比 1143.9（622.0）µg/mL]（P=0.002），并且从基线到 A2 的血栓素-1 显著下降[-4.43（8.0）µg/mL 比 1.7（11.3）µg/mL]（P=0.04），与无应答者相比。在接受安慰剂的应答者中未观察到类似的变化。这些生物标志物没有观察到一致的趋势。